BCAX vs. ACAD, MOR, XENE, AMRX, RXRX, TWST, BHC, NAMS, HCM, and MLTX
Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Bicara Therapeutics vs.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
ACADIA Pharmaceuticals received 884 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 73.05% of users gave ACADIA Pharmaceuticals an outperform vote.
In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 8 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.64 beat ACADIA Pharmaceuticals' score of 0.63 indicating that Bicara Therapeutics is being referred to more favorably in the news media.
96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ACADIA Pharmaceuticals has a net margin of 13.83% compared to Bicara Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Bicara Therapeutics' return on equity.
Bicara Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals currently has a consensus price target of $23.93, indicating a potential upside of 39.23%. Bicara Therapeutics has a consensus price target of $36.50, indicating a potential upside of 172.40%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than ACADIA Pharmaceuticals.
Summary
ACADIA Pharmaceuticals beats Bicara Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Bicara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCAX) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy BCAX Stock Free BCAX Stock Alerts